Navaux, Inc.

Based in Arkansas, US, and founded in 2019, Navaux, Inc. is a healthcare diagnostics company focused on advancing early cancer detection through biomarker testing to address the challenges of metastatic cancer diagnosis. In July 2024, Navaux, Inc. raised venture funding.

As of December 2024, Don E. Fowler is the CEO of the company. Navaux’s flagship product, the ACTIVH test, identifies activated circulating hepsin, a biomarker associated with metastatic diseases. The ACTIVH test is a blood-based diagnostic tool designed to detect activated circulating hepsin levels, aiding in the identification of over 50 types of cancer.

Requiring only a single blood draw, the test establishes a baseline for tracking health changes. Its noninvasive approach makes it a practical option for patients and physicians seeking early detection solutions. ACTIVH is intended to complement existing screening methods, offering actionable insights that guide subsequent diagnostic steps. Additionally, the biomarkers identified by ACTIVH present potential targets for future therapies, aiming to improve treatment efficacy and reduce adverse side effects.

The company generates revenue by offering the ACTIVH test to patients at a cost of USD 99 per test. This pricing provides a direct revenue stream from individuals seeking early cancer detection and guidance for further diagnostic screening, leveraging the affordability and accessibility of the blood-based diagnostic tool. The company plans to use its proceeds from July 2024 funding to enhance its test for early cancer detection.